id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9392 R32895 |
Coste (Valproate) (Controls unexposed, NOS), 2020 | Neonatal condition | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 0.91 [0.75;1.11] C | 119/991 222,201/1,710,441 | 222,320 | 991 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9441 R33152 |
Wen (Valproate) (Mixed indications), 2017 | Abnormal condition of new born | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.35 [0.87;2.08] C | 23/226 3,407/43,956 | 3,430 | 226 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9297 R32325 |
D'Souza (Valproate) (Controls unexposed, disease free), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
10.27 [0.19;570.25] C excluded (control group) |
1/1 6/62 | 7 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9298 R32354 |
D'Souza (Valproate) (Controls unexposed, sick), 1991 | Neonatal conditions | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 4.33 [0.06;320.42] C | 1/1 2/8 | 3 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.05 [0.76;1.44] | 225,753 | 1,218 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, NOS; 2: Valproate) (Mixed indications; 3: Valproate) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9297